- Trials with a EudraCT protocol (30)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
30 result(s) found for: Late termination of pregnancy.
Displaying page 1 of 2.
EudraCT Number: 2012-005042-37 | Sponsor Protocol Number: P-AG-E-4 | Start Date*: 2013-05-10 |
Sponsor Name:Bionorica SE | ||
Full Title: Prospective, double-blind, placebo-controlled, parallel-group, multi-centre randomized clinical trial to proof efficacy and safety of 20 mg (2 tablets of 10 mg) VAC BNO 1095 FCT in patients sufferi... | ||
Medical condition: Cyclic mastodynia and PMS | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DE (Prematurely Ended) PL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-001984-53 | Sponsor Protocol Number: ETHIG II | Start Date*: 2006-10-11 | |||||||||||
Sponsor Name:Friedrich-Schiller-Universität Jena | |||||||||||||
Full Title: Effectiveness of Dalteparin Therapy as Intervention in recurrent pregnancy loss | |||||||||||||
Medical condition: Pregnant women with a history of recurrent pregnancy loss, defined as: - 2 or more early (< 12 weeks of gestation) pregnancy losses or - 1 or more late (> 12 weeks of gestation) pregnancy loss | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006560-11 | Sponsor Protocol Number: FARM7J4HCH | Start Date*: 2009-02-24 |
Sponsor Name:OSPEDALE POLICLINICO S. MATTEO | ||
Full Title: Prevention of human cytomegalovirus (HCMV) mother-to-fetus transmission by administration of virus-specific hyperimmune globulin to pregnant women with primary HCMV infection | ||
Medical condition: Pregnant women with primary HCMV infection. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-000452-34 | Sponsor Protocol Number: 3004 | Start Date*: 2013-11-19 | |||||||||||
Sponsor Name:Steno Diabetes Center | |||||||||||||
Full Title: Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuria | |||||||||||||
Medical condition: Patients with type 2 diabetes mellitus and normoalbuminuria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) IT (Completed) GB (Completed) NL (Completed) ES (Completed) CZ (Completed) GR (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000899-23 | Sponsor Protocol Number: CORT125134-451 | Start Date*: 2016-08-16 | |||||||||||
Sponsor Name:Corcept Therapeutics Incorporated | |||||||||||||
Full Title: Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing’s Syndrome | |||||||||||||
Medical condition: Endogenous Cushing’s Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) HU (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001768-48 | Sponsor Protocol Number: 701-301 | Start Date*: 2013-11-27 | |||||||||||
Sponsor Name:BioMarin Pharmaceutical Inc | |||||||||||||
Full Title: A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects with Late-onset Pompe Disease | |||||||||||||
Medical condition: Pompe disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) IT (Completed) PT (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023561-22 | Sponsor Protocol Number: POM-001 | Start Date*: 2011-08-15 | |||||||||||
Sponsor Name:BioMarin Pharmaceutical Inc | |||||||||||||
Full Title: A Phase 1/2 Open-label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic and Preliminary Efficacy of BMN 701 (GILT-tagged Recombinant human GAA) in Patients with Late-onset Pompe... | |||||||||||||
Medical condition: Pompe disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001489-41 | Sponsor Protocol Number: P00003466 | Start Date*: 2018-07-02 | |||||||||||
Sponsor Name:Karolinska Universitetssjukhuset | |||||||||||||
Full Title: Radiation- and alkylator-free hematopoietic cell transplantation for bone marrow failure due to dyskeratosis congenita / telomere disease | |||||||||||||
Medical condition: Dyskeratosis congenita / telomere disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003421-22 | Sponsor Protocol Number: GT005-02 | Start Date*: 2020-01-23 | |||||||||||
Sponsor Name:Gyroscope Therapeutics | |||||||||||||
Full Title: EXPLORE: A phase 2, outcomes assessor-masked, multicentre, randomised study to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with ... | |||||||||||||
Medical condition: Age-related Macular Degeneration (AMD) presents as a progressive loss of vision in the centre of the retina (the macula) resulting in a blurred area or blank spot in the centre of vision. The prima... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) ES (Prematurely Ended) IE (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003168-63 | Sponsor Protocol Number: AMLSG16-10/CPKC412ADE02T | Start Date*: 2012-04-27 |
Sponsor Name:University Hospital Ulm | ||
Full Title: Phase-II study evaluating midostaurin in induction, consolidation and maintenance therapy also after allogeneic blood stem cell transplantation in patients with newly diagnosed acute myeloid leuk... | ||
Medical condition: Patients with confirmed diagnosis of AML or related precursor neoplasm, or acute leukemia of ambiguous lineage (classified according to the World Health Organization (WHO) 2008 classification) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-004066-28 | Sponsor Protocol Number: AMLSG2415 | Start Date*: 2018-04-04 |
Sponsor Name:University Hospital Ulm | ||
Full Title: A Phase II Study with a Safety Run-in Phase Evaluating Vosaroxin With Azacitidine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia and Intermediate/Adverse Genetic Risk or Myelodysplas... | ||
Medical condition: Patients with confirmed diagnosis of acute myeloid leukemia (WHO 2016) and intermediate or adverse genetic risk (according to 2017 ELN recommendations); or patients with myelodysplastic syndrome wi... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2017-000732-34 | Sponsor Protocol Number: ABOXY_2017 | Start Date*: 2017-06-21 | ||||||||||||||||||||||||||
Sponsor Name:Mech-Sense, Dept. Gastroenterology & Hepatology, Aalborg University Hospital | ||||||||||||||||||||||||||||
Full Title: Oral Controlled Release Formulations to Patients with Gastrointestinal Dysfunction – Is the Release of Drug and the Absorption Impaired? | ||||||||||||||||||||||||||||
Medical condition: Healthy (pain) and patients (pain). | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-001823-38 | Sponsor Protocol Number: AB65/18 | Start Date*: 2018-11-26 | |||||||||||
Sponsor Name:Technische Universität München, Fakultät für Medizin vertreten durch den Dekan | |||||||||||||
Full Title: A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urot... | |||||||||||||
Medical condition: Locally advanced urothelial bladder cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003160-27 | Sponsor Protocol Number: Sobi.PEGCET-101 | Start Date*: 2022-05-31 |
Sponsor Name:Swedish Orphan Biovitrum AB | ||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Cold Agglutinin Disease (CAD) | ||
Medical condition: Patients with Cold Agglutinin Disease (CAD) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) NO (Prematurely Ended) HU (Prematurely Ended) AT (Completed) IT (Prematurely Ended) BG (Completed) ES (Prematurely Ended) FI (Prematurely Ended) BE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-002431-30 | Sponsor Protocol Number: GT005-03 | Start Date*: 2020-10-21 | |||||||||||
Sponsor Name:Gyroscope Therapeutics | |||||||||||||
Full Title: HORIZON: A Phase II, open-label, outcomes-assessor masked, multicentre, randomised,controlled study to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal inj... | |||||||||||||
Medical condition: Age-related Macular Degeneration (AMD) presents as a progressive loss of vision in the centre of the retina (the macula) resulting in a blurred area or blank spot in the centre of vision. The prima... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012598-37 | Sponsor Protocol Number: DUT-MD-304 | Start Date*: 2010-01-29 | |||||||||||
Sponsor Name:Forest Research Institute, Inc. | |||||||||||||
Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DUTOGLIPTIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS ON BACKGROUND TREATMENT WIT... | |||||||||||||
Medical condition: Type 2 diabetes mellitus (T2DM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) LT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005531-13 | Sponsor Protocol Number: MED3-201401 | Start Date*: 2015-11-26 |
Sponsor Name:Univerity of Bonn | ||
Full Title: Multicenter, open-label single arm phase II study testing the tolerability and the efficacy of Bosutinib step-in dosing in Chronic Phase CML patients intolerant or refractory to previous Imatinib, ... | ||
Medical condition: Chronic Phase Chronic myelogenous leukaemia( CP-CML) patients who either developed intolerance or treatment failure to previous Imatinib, Dasatinib or Nilotinib as 1st or 2nd line therapy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-017524-36 | Sponsor Protocol Number: DUT-MD-403 | Start Date*: 2010-05-18 | |||||||||||
Sponsor Name:Forest Research Institute, Inc. | |||||||||||||
Full Title: A Phase III, Multicenter, Double-blind, Active-Controlled, 52-Week Extension Study to Evaluate the Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background ... | |||||||||||||
Medical condition: Type 2 diabetes mellitus (T2DM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001805-28 | Sponsor Protocol Number: POM-002 | Start Date*: 2012-07-03 | |||||||||||
Sponsor Name:BioMarin Pharmaceutical Inc | |||||||||||||
Full Title: A Long-Term Study for Extended BMN 701Treatment of Patients with Pompe Disease who have Participated in a BMN 701 Study | |||||||||||||
Medical condition: Pompe disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003096-35 | Sponsor Protocol Number: CORT125134-455 | Start Date*: 2019-06-19 | |||||||||||
Sponsor Name:Corcept Therapeutics Incorporated | |||||||||||||
Full Title: Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant | |||||||||||||
Medical condition: Endogenous Cushing syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) BG (Completed) AT (Completed) PL (Completed) ES (Ongoing) DE (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
